乳腺癌患者化疗期间临时卵巢抑制以保护卵巢功能与生育力:意大利肿瘤内科协会基于GRADE方法的证据评价与推荐
意大利肿瘤内科协会(AIOM)临床实践指南专家组采用GRADE方法,针对乳腺癌患者化疗期间使用促黄体生成素释放激素类似物(LHRHa)临时卵巢抑制以保护卵巢功能和生育力的临床效用问题进行评价,最终形成强推荐支持使用该策略。本文旨在根据截至2016年1月发表的新数据更新和总结该策略的证据。
要点
- AIOM指南专家组采用GRADE方法评价化疗期间LHRHa临时卵巢抑制用于乳腺癌患者卵巢功能与生育力保护。
- 将卵巢功能保护和生育力保护判定为决策的关键结局。
- GRADE评价结果为强推荐支持使用该策略保护乳腺癌患者的卵巢功能与生育力。
核心结论
- 根据所进行的GRADE评价,结果为强推荐支持使用化疗期间LHRHa临时卵巢抑制这一选项来保护乳腺癌患者的卵巢功能与生育力。
研究设计与样本
- 意大利肿瘤内科协会(AIOM)癌症患者生育力保护临床实践指南专家组针对乳腺癌患者化疗期间LHRHa临时卵巢抑制保护卵巢功能与生育力的临床效用问题应用GRADE方法进行证据评价。
- 本稿件旨在根据截至2016年1月发表的新数据,按照GRADE流程更新和总结该策略的证据。
主要发现
- 早发型乳腺癌绝经前女性使用化疗可能导致卵巢早衰和后续不孕。
- 在可用的生育力保护策略中,化疗期间使用LHRHa对卵巢进行药物保护有可能在抗癌治疗后恢复卵巢功能与生育力,但该策略的可能疗效与临床应用近年来备受争议。
- 将卵巢功能保护与生育力保护判定为决策的关键结局。
- 识别了三种可能的危害结局:LHRHa相关毒性、同期LHRHa与化疗之间可能的拮抗作用、以及化疗所致卵巢早衰缺乏预后影响。
关键数值与推荐
- GRADE评价结果为强推荐支持使用化疗期间LHRHa临时卵巢抑制以保护乳腺癌患者的卵巢功能与生育力。
临床怎么用
- 原文未据此给出具体临床操作推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of premature ovarian failure and subsequent infertility are possible consequences of chemotherapy use in pre-menopausal women with early-stage breast cancer. Among the available strategies for fertility preservation, pharmacological protection of the ovaries using luteinising hormone-releasing hormone analogues (LHRHa) during chemotherapy has the potential to restore ovarian function and fertility after anticancer treatments; however, the possible efficacy and clinical application of this strategy has been highly debated in the last years. Following the availability of new data on this controversial topic, the Panel of the Italian Association of Medical Oncology (AIOM) Clinical Practice Guideline on fertility preservation in cancer patients decided to apply the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) methodology around the relevant and current question on the clinical utility of temporary ovarian suppression with LHRHa during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients. To answer this question, preservation of ovarian function and fertility were judged as critical outcomes for the decision-making. Three possible outcomes of harm were identified: LHRHa-associated toxicities, potential antagonism between concurrent LHRHa and chemotherapy, and lack of the prognostic impact of chemotherapy-induced premature ovarian failure. According to the GRADE evaluation conducted, the result was a strong positive recommendation in favour of using this option to preserve ovarian function and fertility in breast cancer patients. The present manuscript aims to update and summarise the evidence for the use of this strategy in light of the new data published up to January 2016, according to the GRADE process.
引用
- Lambertini M, Cinquini M, Moschetti I, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer. 2016. PMID: 27940355. doi:10.1016/j.ejca.2016.10.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。